Dr Jones previously led the pharma business unit for Devgen in Ghent, Belgium. Prior to that, he was vice president of business development at BioRexis Pharmaceuticals. Most recently, Dr Hunt served as executive director and head of RNAi development at Pfizer’s Research Technology Center.
Lauren Silverman, member of the board of directors at Ascent, said: “We are pleased to announce the appointment of Dr Frederick Jones as president and CEO to lead the strong Ascent team of experienced scientists and professionals.”
Ascent has been funded with a $19 million series A investment by a syndicate of healthcare venture investors including Novartis Option Fund, Healthcare Ventures and TVM Capital.